Four New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read moreTexas Retina Associates Announces the Retirement of David Callanan, MD
It is with mixed emotions that we announce the retirement of David Callanan, MD, from Texas Retina Associates effective June 30, 2022. He has been caring for patients at our practice since
read moreDr. Abbey Spoke About Complications of a Compounded Medication Used in “Dropless” Cataract Surgery at the Vit-Buckle Society (VBS) Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, presented “Complications of Compounded Moxifloxacin-Triamcinolone” at the 10th Annual Meeting of the Vit-Buckle Society (VBS) held March 24 – 26, 2022, in Las Vegas. He
read moreDavid Callanan, MD, Presented Uveitis Clinical Trial Results at American Society of Retina Specialists 2019 Annual Meeting
Texas Retina Associates’ David Callanan, MD, presented the results of a clinical trial on a promising new treatment for chronic posterior segment uveitis at the American Society of Retina Specialists (ASRS) 2019
read more